Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 51.26% is 47% above its 5-year average of 34.93%, near the high end of its 5-year range (-83.51%–67.04%).
2.99% above its 12-month average of 49.77%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 67.04%.
GROSS MARGIN
51.26%
GROSS MARGIN AVG TTM
49.77%
GROSS MARGIN AVG 3Y
37.42%
GROSS MARGIN AVG 5Y
34.93%
GROSS MARGIN AVG 10Y
39.44%
GROSS MARGIN AVG 15Y
40.87%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.99%
CURRENT VS 3Y AVG
+37.00%
CURRENT VS 5Y AVG
+46.75%
CURRENT VS 10Y AVG
+29.97%
CURRENT VS 15Y AVG
+25.42%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
+26.76%
vs the sector median at left
Nutex Health, Inc.
Market Cap
$1.53B
Gross Margin
51.26%
TTM Avg
49.77%
3Y Avg
37.42%
5Y Avg
34.93%
Market Cap
$1.53B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
66.67%
Market Cap
$1.54B
Gross Margin
97.47%
TTM Avg
96.23%
3Y Avg
48.12%
5Y Avg
65.41%
Market Cap
$1.49B
Gross Margin
57.87%
TTM Avg
56.73%
3Y Avg
61.85%
5Y Avg
-49.66%
Market Cap
$1.49B
Gross Margin
33.71%
TTM Avg
32.28%
3Y Avg
31.46%
5Y Avg
31.45%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nutex Health, Inc. (NUTX) | $1.53B | 51.26% | 49.77% | 37.42% | 34.93% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | 100.00% | 100.00% | 100.00% | 66.67% |
| uniQure N.V. (QURE)vs › | $1.53B | 89.53% | 60.98% | 58.20% | 16.96% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 97.47% | 96.23% | 48.12% | 65.41% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 73.09% | 81.06% | 86.06% | 90.71% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 57.87% | 56.73% | 61.85% | -49.66% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 33.71% | 32.28% | 31.46% | 31.45% |
| Omnicell, Inc. (OMCL)vs › | $1.59B | 44.77% | 42.62% | 43.56% | 44.93% |
| GH Research PLC (GHRS)vs › | $1.46B | 0.00% | 0.00% | 0.00% | 0.00% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
51.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 67.04% |
| 2026-03-31 | 42.37% |
| 2025-12-31 | 30.42% |
| 2025-09-30 | 57.83% |
| 2025-06-30 | 51.20% |
| 2025-03-31 | 55.88% |
| 2024-12-31 | 54.98% |
| 2024-09-30 | 27.82% |
| 2024-06-30 | 29.65% |
| 2024-03-31 | 15.06% |
| 2023-12-31 | 18.97% |
| 2023-09-30 | 18.83% |
| 2023-06-30 | 16.37% |
| 2023-03-31 | 8.61% |
| 2022-12-31 | 0.99% |
| 2022-09-30 | -83.51% |
| 2022-06-30 | 11.44% |
| 2022-03-31 | 45.26% |
| 2021-12-31 | 35.09% |
| 2021-09-30 | 64.43% |
| 2021-06-30 | 46.39% |
| 2021-03-31 | 21.19% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 39.75% |
| 2020-06-30 | 6.87% |
| 2020-03-31 | 28.39% |
| 2019-12-31 | 4205.95% |
| 2019-09-30 | 57.17% |
| 2019-06-30 | 15.95% |
| 2019-03-31 | 20.59% |
| 2018-12-31 | -510.48% |
| 2018-09-30 | -706.98% |
| 2018-06-30 | -4792.49% |
| 2018-03-31 | -4239.15% |
| 2017-12-31 | 7782.11% |
| 2017-09-30 | 41.02% |
| 2017-06-30 | -7304.40% |
| 2017-03-31 | -202.02% |
| 2016-09-30 | 98.47% |
| 2016-06-30 | 94.64% |
| 2016-03-31 | 97.65% |
| 2011-12-31 | 37.16% |
| 2011-09-30 | 36.45% |
| 2011-06-30 | 36.60% |
| 2011-03-31 | 51.96% |
| 2010-12-31 | 19.14% |
| 2010-09-30 | 55.51% |
| 2010-06-30 | 43.72% |
| 2010-03-31 | 71.39% |
| 2009-12-31 | 0.00% |
